SciELO - Scientific Electronic Library Online

vol.80 issue6Molecular epidemiology of tuberculosis: achievements and challenges to current knowledgeControlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework author indexsubject indexarticles search
Home Page  

Services on Demand




Related links


Bulletin of the World Health Organization

Print version ISSN 0042-9686


GINSBERG, Ann M.. What's new in tuberculosis vaccines?. Bull World Health Organ [online]. 2002, vol.80, n.6, pp.483-488. ISSN 0042-9686.

Over the past 10 years, tuberculosis (TB) vaccine development has resurged as an active area of investigation. The renewed interest has been stimulated by the recognition that, although BCG is delivered to approximately 90% of all neonates globally through the Expanded Programme on Immunization, Mycobacterium tuberculosis continues to cause over 8 million new cases of TB and over 2 million deaths annually. Over one hundred TB vaccine candidates have been developed, using different approaches to inducing protective immunity. Candidate vaccines are typically screened in small animal models of primary TB disease for their ability to protect against a virulent strain of M. tuberculosis. The most promising are now beginning to enter human safety trials, marking real progress in this field for the first time in 80 years.

Keywords : BCG vaccine; Mycobacterium bovis [immunology]; Mycobacterium bovis [genetics]; Mycobacterium tuberculosis [immunology]; Mycobacterium tuberculosis [genetics]; Drug evaluation; Preclinical; Models; Animal; Clinical trials; Phase I; Research.

        · abstract in French | Spanish     · text in English     · English ( pdf )